GE-Danaher pharma deal is a win-win remedy tombuerkle rob_cyran
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
GE to Sell BioPharma Business to Danaher for $21.4 BillionGeneral Electric to sell biopharma unit to Danaher for $21.4 billion, part of a strategy to reduce leverage and boost its balance sheet
Read more »
GE withdraws plans for Healthcare IPO after Danaher deal: BloombergGeneral Electric will no longer seek an IPO for its health-care unit following the sale of its biopharma business, CEO Larry Culp told Bloomberg on Monday.
Read more »
GE stock rockets after $21 billion deal with Danaher, but remains below key chart levelShares of General Electric Co. rocket after a deal to sell the company’s biopharma business for $21.4 billion in cash to Danaher Corp, but remain on track to extend their longest streak below the widely watched 200-day moving average in at least 40 years.
Read more »
GE shares surge 13% after Danaher agrees to buy biopharma business for $21.4 billionGE is selling its biopharma unit for $21.4 billion to Danaher, saying it will use the money to reduce leverage and strengthen its balance sheet.
Read more »
GE's stock soars after deal to sell biopharma business to Danaher for $21.4 billionShares of General Electric Co. shot 8.8% in premarket trade Monday, after the industrial conglomerate agreed to sell its biopharma business to Danaher Corp. for $21.4 billion in cash. "Today's transaction is a pivotal milestone," said GE Chief Executive Lawrence Culp. "It demonstrates that we are executing on our strategy by taking thoughtful and deliberate action to reduce leverage and strengthen our balance sheet." Culp had served as CEO of Danaher from 2001 to 2014. Danaher said it expects to finance the deal with $3 billion from an equity offering, cash on hand and the issuance of debt. Danaher expects the deal, which is expected to close in the fourth quarter of 2019, to reduce net earnings by share by $1.15 to $1.20 in the first full year, but add to adjusted EPS by about 45 cents to 50 cents. GE's stock has soared 34.4% over the past three months through Friday, while Danaher shares have climbed 10.8% and the Dow Jones Industrial Average has gained 7.2%.
Read more »
GE's stock soars after deal to sell biopharma business to Danaher for $21.4 billionShares of General Electric Co. shot 8.8% in premarket trade Monday, after the industrial conglomerate agreed to sell its biopharma business to Danaher Corp. for $21.4 billion in cash. "Today's transaction is a pivotal milestone," said GE Chief Executive Lawrence Culp. "It demonstrates that we are executing on our strategy by taking thoughtful and deliberate action to reduce leverage and strengthen our balance sheet." Culp had served as CEO of Danaher from 2001 to 2014. Danaher said it expects to finance the deal with $3 billion from an equity offering, cash on hand and the issuance of debt. Danaher expects the deal, which is expected to close in the fourth quarter of 2019, to reduce net earnings by share by $1.15 to $1.20 in the first full year, but add to adjusted EPS by about 45 cents to 50 cents. GE's stock has soared 34.4% over the past three months through Friday, while Danaher shares have climbed 10.8% and the Dow Jones Industrial Average has gained 7.2%.
Read more »
GE withdraws plans for Healthcare IPO after Danaher deal: BloombergGeneral Electric will no longer seek an IPO for its health-care unit following the sale of its biopharma business, CEO Larry Culp told Bloomberg on Monday.
Read more »
GE stock rockets after $21 billion deal with Danaher, but remains below key chart levelShares of General Electric Co. rocket after a deal to sell the company’s biopharma business for $21.4 billion in cash to Danaher Corp, but remain on track to extend their longest streak below the widely watched 200-day moving average in at least 40 years.
Read more »
GE to Sell BioPharma Business to Danaher for $21.4 BillionGeneral Electric to sell biopharma unit to Danaher for $21.4 billion, part of a strategy to reduce leverage and boost its balance sheet
Read more »